New antimicrobial agents on the horizon

Antibiotic resistance issues necessitate the continued discovery and development of new antibacterial agents. Efforts are ongoing in two approaches to find new compounds that are effective against antibiotic-resistant pathogens. These efforts involve modification of existing classes including fluoro...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2011-12, Vol.82 (11), p.1528-1539
Main Authors: Bush, Karen, Pucci, Michael J.
Format: Article
Language:English
Subjects:
Aminoglycoside antibiotics
aminoglycosides
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotic
Antibiotic resistance
Antimicrobial agents
Antimicrobial Cationic Peptides - pharmacology
Antimicrobial Cationic Peptides - physiology
Bacterial target
Biological and medical sciences
Cell Wall - drug effects
Clinical trial
Developmental stages
DNA Replication - drug effects
DNA, Bacterial - antagonists & inhibitors
DNA, Bacterial - biosynthesis
Drug discovery
Drug Resistance, Bacterial
Fatty Acids - antagonists & inhibitors
Fatty Acids - biosynthesis
Fluoroquinolones
Humans
Medical sciences
Multidrug Resistance-Associated Proteins - antagonists & inhibitors
Pathogens
Pharmacology. Drug treatments
Protein Synthesis Inhibitors - chemistry
Protein Synthesis Inhibitors - pharmacology
Tetracyclines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibiotic resistance issues necessitate the continued discovery and development of new antibacterial agents. Efforts are ongoing in two approaches to find new compounds that are effective against antibiotic-resistant pathogens. These efforts involve modification of existing classes including fluoroquinolones, tetracyclines, aminoglycosides, and β-lactams and identification of inhibitors against previously unexploited antibacterial targets. Examples of both approaches are described here with emphasis on compounds in late pre-clinical or clinical stages of development.
ISSN:0006-2952
1873-2968
DOI:10.1016/j.bcp.2011.07.077